Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies - Schöffski, Patrick; Tan, Daniel S.-W.; Martín, Miguel; Ochoa-de-Olza, María; Sarantopoulos, John; Carvajal, Richard D.; Kyi, Chrisann; Esaki, Taito; Prawira, Amy; Akerley, Wallace; Braud, Filippo De; Hui, Rina; et al. (Journal for ImmunoTherapy of Cancer, 2022)
Gesehen am 07.04.2022